The International Nurses Society of Addictions announces the following
IntNSA / PCSS sponsored webinar:
Initiating Buprenorphine for Patients Using Fentanyl
DATE & TIME
Friday, April 7
(Duration: 1 hour)
Cost: $0, Free to all Attendees
HOW TO REGISTER
The United States is currently experiencing the worst overdose crisis in our history, driven by the increasing potency and variety of opioids, central
nervous system depressants, and stimulants present throughout the drug supply. Treatment of opioid use disorder with buprenorphine is a well demonstrated and empirically validated intervention that reduces opioid use, reduces the risk of overdose, and increases treatment retention. Fentanyl’s increasingly presence within the United States’ drug supply is associated with increasingly common clinical challenge of buprenorphine-precipitated withdrawal during standard dosing approaches, due to fentanyl’s pharmacologic properties. Despite these
challenges, patients with opioid use disorder involving fentanyl as compared with opioid use disorder without fentanyl are both well demonstrated to experience similar rates of treatment retention after buprenorphine is initiated. There is not yet a consensus on a uniform consensus on how to best adapt buprenorphine initiation protocols for patients whose opioid use disorder involves fentanyl.
This webinar will review variations on buprenorphine dosing that can be
considered for patients with opioid use disorder involving fentanyl. The
presenters will review the evidence for and describe low dose buprenorphine initiation of protocols, high dose buprenorphine initiation of protocols, approaches to help support patients stop using full agonist opioids for a longer period of time, and a clinical approach to referring patients to alternative medications for opioid use disorder.
Compare and contrast low-dose, high-dose, standard dose, and
variations for the timing and setting for initiating buprenorphine to treat opioid use disorder involving fentanyl.
Design a treatment plan that factors in the risks and benefits of buprenorphine to treat opioid use disorder in consideration of the set, setting, and patient’s priorities for their opioid use disorder treatment.
Recognize the limitations of buprenorphine treatment of opioid use disorder and how to refer to alternative treatments.
WHO SHOULD ATTEND
This presentation was developed for Nurses, MAT Team Providers, Addictions Specialists, SUD Project Directors, Managers, and Facilitators.
Brian Hurley, MD, MBA, DFASAM, FAPA, President-Elect; American Society of Addiction Medicine
Brian is an addiction physician based in California and the Medical Director of the Division of Substance Abuse Prevention and Control for the Los Angeles County Department of Public Health. Brian currently serves as President-Elect of the ASAM Board of Directors and is slated to become the President of ASAM in April 2023. He is the Clinical Director of the Addiction Treatment Starts Here programs through the Center for Care Innovations, focused on increasing the delivery of medications for addiction treatment in California’s community health centers. He is a senior researcher at the Friends Research Institute; and is a primary investigator on a Tobacco Related Disease Prevention Program-funded project integrating smoking cessation services into community mental health centers and patient-centered medical homes. Additionally, Dr. Hurley is the grant lead for several Medications for Addiction Treatment Access Points’ projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is on faculty at the University of California, Los Angeles, as a volunteer assistant clinical professor of addiction medicine in the department of family medicine.
This course has been approved by the California Board of Registered Nursing for a maximum of 1.00 Nursing Contact Hour. The licensee must retain this document for a period of four (4) years after the course concludes.
Funding for this initiative was made possible (in part) by grant no. 6H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.